I caught up by teleconference recently with Countable Labs CEO Giovanna Prout, fresh off Countable Labs' $26M equity fundraising - a round which was oversubscribed. Top on my agenda: what is Prout's vision to turn that money into products. And how will Countable balance building molecular tools vs. applying those tools to clinical problems?
